TICKERNERD
Menu
ALECALECHealthcare · Biotechnology

ALEC Stock Forecast: Alector, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$1.96
−3.92% on the day

The 8 Wall Street analysts covering Alector, Inc. hold a median 12-month price target of $2 — +2.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$218.8M
Ticker Nerd rank
41 / 100
Median analyst target
$2.00
Analysts covering
8
Total return, dividends reinvested
1W
+10.1%
1M
+41.0%
YTD
+25.6%
1Y
−20.3%
From 52W high
−41.0%
From 52W low
+71.9%
$1.14
$3.32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALEC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alector, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
68
Revisions
67
Issuance
64
Momentum
45
Accruals
43
Growth
37
Quality
33
Value
32
Volatility
29

Size (68): Smaller than most of the companies we track.

Volatility (29): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALEC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALEC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26ALECHigh $6.00Median $2.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
3 Buy3 Hold2 Sell
Low $1.00Median $2.00High $6.00

The green dot is the last close — the median target sits +2.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Apr 2026Cantor FitzgeraldUpgradeOverweight—
10 Mar 2026BTIGUpgradeBuy—
22 Oct 2025BTIGDowngradeNeutral—
22 Oct 2025Cantor FitzgeraldDowngradeNeutral—
22 Oct 2025HC Wainwright & Co.MaintainsBuy—
22 Oct 2025TD CowenDowngradeHold—
22 Oct 2025William BlairDowngradeMarket Perform—
25 Sept 2025BTIGReiteratesBuy—
28 July 2025MizuhoUpgradeOutperform—
9 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025Morgan StanleyAssumesUnderweight$3.00 → $1.50
27 Feb 2025HC Wainwright & Co.ReiteratesBuy—
16 Dec 2024StifelDowngradeHold—
26 Nov 2024BTIGMaintainsBuy—
26 Nov 2024Cantor FitzgeraldReiteratesOverweight—
26 Nov 2024Morgan StanleyDowngradeUnderweight—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
17 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
29 July 2024Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALEC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ALEC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

Alector, Inc. (ALEC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 83% of US stocks

Price / sales
15.8×

Cheaper than 11% of US stocks

Price / book
−21.9×

Cheaper than 98% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−57.8%

Higher than 4% of US stocks

Earnings growth (YoY)
−57.8%

Higher than 9% of US stocks

Gross margin
—
Operating margin
−734.7%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−385.1%

Higher than 4% of US stocks

Return on assets
−27.6%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALEC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALECAlector, Inc.$218.8M
41
NERVMinerva Neurosciences, Inc.$213.4M
31
ANTXAN2 Therapeutics, Inc.$215.3M
74
IVVDInvivyd, Inc.$212.4M
19
YDESYD Bio Ltd.$210.2M
53
TNXPTonix Pharmaceuticals Holding Corp.$218.0M
21
IMUXImmunic, Inc.$218.8M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alector, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALEC news & analysis

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026positive

Alector reported a second-quarter loss of $0.21 per share, narrower than the Zacks Consensus Estimate of a $0.24 loss and an improvement over the $0.30 loss from the same period last year. The company also topped revenue estimates for the quarter.

Why it matters — ALEC watchers would note that the company beat earnings expectations and narrowed its year-over-year loss, a modest improvement in its financial performance.

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 6 Aug 2026positive

Alector reported its second quarter 2026 financial results and provided a business update. The company highlighted advancement of its ABC blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as its lead ABC-enabled anti-amyloid beta antibody program for Alzheimer's disease, alongside continued progress on AL064/AL164 (Tau siRNA) and AL050 (GCase enzyme replacement therapy for Parkinson's disease).

Why it matters — ALEC watchers would care because the update details pipeline progress across three of Alector's key ABC-enabled programs for Alzheimer's and Parkinson's diseases.

FAQ

Frequently asked questions about ALEC stock

What is the ALEC stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Alector, Inc. have a median 12-month price target of $2, with estimates ranging from $1 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALEC stock a buy right now?

Of the 8 analysts covering Alector, Inc., 3 rate it a Buy, 3 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Alector, Inc. 41 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALEC?

As at 15 Aug 2026, Alector, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (68 of 100).

Will ALEC stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +2.0% from the last close, and Ticker Nerd's factor model ranks Alector, Inc. 41 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALEC stock forecast for 2030?

No analyst covering Alector, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALEC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $6 over the next 12 months.

How has ALEC stock performed over the past year?

Alector, Inc. returned -20.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alector, Inc. do?

Alector Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to counteract the progression of neurodegenerative diseases such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease.

What is the latest news on ALEC?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates". Alector reported a second-quarter loss of $0.21 per share, narrower than the Zacks Consensus Estimate of a $0.24 loss and an improvement over the $0.30 loss from the same period last year. The company also topped revenue estimates for the quarter.

Company

About Alector, Inc.

Alector Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to counteract the progression of neurodegenerative diseases such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company harnesses insights from human genetics, neuroscience, and immunology to advance an innovative pipeline of therapeutic candidates designed to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function in the brain. Key programs include latozinemab, a progranulin-elevating monoclonal antibody previously investigated for frontotemporal dementia due to GRN mutations, and nivisnebart for early Alzheimer's disease, alongside preclinical efforts like AL137, an anti-amyloid beta antibody, AL050, a GCase enzyme replacement therapy for Parkinson's and Lewy body dementia, and others targeting tau, alpha-synuclein, and NLRP3. Alector employs its proprietary Alector Brain Carrier technology to enhance blood-brain barrier penetration for these immuno-neurology therapies. Founded in 2013 and headquartered in South San Francisco, California, Alector Inc. plays a significant role in addressing unmet needs in neurodegeneration treatment through genetically validated approaches.

CEO Dr. Arnon Rosenthal Ph.D. · 103 employees · United States · https://www.alector.com